score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Investigate Actionability	Inferential			Copy Number	CD274	Deletion				0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. 	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.	https://doi.org/10.1056/NEJMoa1501824													0				CD274 Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Copy Number	MLH3	Amplification				0.0	0.0																					0				MLH3 Amplification		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Copy Number	SETBP1	Deletion				0.0	0.0																					0				SETBP1 Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Copy Number	JAK2	Deletion				0.0	0.0																					0				JAK2 Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Copy Number	FLCN	Deletion				0.0	0.0																					0				FLCN Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Copy Number	EML4	Deletion				0.0	0.0																					0				EML4 Deletion		MEL-IPI_Pat106	MEL-IPI_Pat106-Tumor-SM-4CU6T	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), nan, POLE p.S1419fs (Frameshift)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), nan, POLE p.S1419fs (Frameshift)		MEL-IPI_Pat106		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.629																									0				COSMIC Signature (version 2) 1 (63%)		MEL-IPI_Pat106		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.311																									0				COSMIC Signature (version 2) 15 (31%)		MEL-IPI_Pat106		
